Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1]. |
In vitro | Anti-inflammatory agent 17 (compound 5b) (10 μM; 24 h) exhibits no toxicity in J774a.1 cells and, at concentrations of 1.25, 2.5, 5, and 10 μM over 2 hours, inhibits IL-6 (IC50 = 8.254 μM) and TNF-α (IC50 = 2.576 μM) production in a dose-dependent manner [1]. |
In vivo | The anti-inflammatory agent 17, when administered intragastrically at a dosage of 20 mg/kg, has demonstrated a protective effect against lipopolysaccharide (LPS)-induced acute lung injury (ALI) in C57/BL6 mice [1]. |
Molecular Weight | 357.4 |
Formula | C20H23NO5 |
Cas No. | 2763226-84-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.